Table II.
Prevalence of HTN According to Lipodystrophy Defined Clinically and by FMR
| HTN | Lipodystrophy Defined Clinically | P Value | Lipodystrophy Defined by FMR | P Value | ||||
|---|---|---|---|---|---|---|---|---|
| Total | Without CL | With CL | Total | Without L | With L | |||
| N=364 | n=149 | n=215 | N=221 | n=118 | n=103 | |||
| Without HTN, No. (%) | 239 (65.7) | 100 (67.1) | 139 (64.7) | .708 | 140 (63.3) | 80 (67.8) | 60 (58.3) | .184 |
| With HTN, No. (%) | 125 (34.3) | 49 (32.9) | 76 (35.3) | 91 (36.7) | 38 (32.2) | 43 (41.7) | ||
| No. | 250 | 87 | 163 | 147 | 57 | 90 | ||
| Men | ||||||||
| Without HTN, No. (%) | 157 (62.8) | 55 (63.2) | 102 (62.6) | 1.000 | 92 (62.6) | 41 (71.9) | 51 (56.7) | .091 |
| With HTN, No. (%) | 93 (37.2) | 32 (36.8) | 61 (37.4) | 55 (37.4) | 16 (28.1) | 39 (43.3) | ||
| No. | 114 | 62 | 52 | 74 | 61 | 13 | ||
| Women | ||||||||
| Without HTN, No. (%) | 82 (71.9) | 45 (72.6) | 37 (71.2) | 1.000 | 48 (64.9) | 39 (63.9) | 9 (69.2) | 1.000 |
| With HTN, No. (%) | 32 (28.1) | 17 (27.4) | 15 (28.8) | 26 (35.1) | 22 (36.1) | 4 (30.8) | ||
Abbreviations: CL, clinical lipodystrophy; FMR, fat mass ratio; HTN, hypertension; L, lipodystrophy.